Atossa TherapeuticsNASDAQ: ATOS

Atossa Therapeutics Inc (NASDAQ:ATOS) has appointed Heather Rees as its new Chief Financial Officer (CFO). The move marks a promotion for Rees, who previously served as the company's senior vice president of finance and principal accounting officer.

SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company's new Chief Financial Officer (CFO). Ms. Rees most recently served as Atossa's Senior Vice President of Finance and Principal Accounting Officer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Atossa Therapeutics Inc (NASDAQ:ATOS). (Nasdaq: ATOS) has announced its support for the SMART (Stockholm MAmmography Risk stratified Trial) study, a new Phase 2 clinical trial aimed at validating an innovative artificial intelligence-driven breast cancer risk assessment model.

SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an innovative, artificial intelligence driven, breast cancer risk assessment model. The SMART (Stockholm MAmmography Risk stratified Trial) study will test an individualized, imaging-based screening model designed to identify women with the highest risk of developing breast cancer in the next two years. If the model is validated for therapeutic use, it could serve as the foundation for a future, Phase 3, trial investigating (Z)-endoxifen in the breast cancer prevention setting. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Does Atossa Genetics Inc. (ATOS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Atossa Therapeutics Inc (NASDAQ:ATOS) has administered the final dose to the last patient in its Karisma-Endoxifen clinical trial, with the goal of decreasing the risk of breast cancer. The phase two trial, which started in November, involved 240 participants, according to Atossa Therapeutics.

Atossa Therapeutics Inc (NASDAQ:ATOS) made significant strides in developing its main clinical asset (Z)-endoxifen for breast cancer prevention and treatment in the first quarter of 2024. Dr. Steven Quay, CEO of the biopharmaceutical company, stated that the quarter ended with a healthy cash balance and no debt, reflecting a period of notable advancement for the company.

Atossa Therapeutics Inc (NASDAQ:ATOS) and Quantum Leap Healthcare Collaborative have started a study to evaluate Atossa's (Z)-endoxifen in combination with Eli Lilly and Co (NYSE:LLY)'s abemaciclib (VERZENIO) in women with ER+/HER2- breast cancer. The study will enroll about 20 women with newly diagnosed ER+/HER2- invasive breast cancer.

Atossa announces promising findings from its phase 2 EVANGELINE clinical trial, indicating that (Z)-endoxifen has the potential to inhibit the progression of ER+ breast cancer.